Phase II study of pembrolizumab (MK-3475) in patients with metastatic castration-resistant prostate cancer (KEYNOTE-199)—study AP 93/16 of the AUO

Heidrun Rexer, M. Graefen, A. Merseburger

1 Citation (Scopus)
Original languageEnglish
JournalUrologe
Volume56
Issue number11
Pages (from-to)1471-1472
Number of pages2
ISSN0340-2592
DOIs
Publication statusPublished - 01.11.2017

Research Areas and Centers

  • Research Area: Luebeck Integrated Oncology Network (LION)

Cite this